HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein


Por: Carrillo, J, Restrepo, C, Rallon, NI, Massanella, M, del Romero, J, Rodriguez, C, Soriano, V, Clotet, B, Benito, JM and Blanco, J

Publicada: 1 jun 2013
Resumen:
Background: Susceptibility to HIV transmission by sexual intercourse has been associated with cellular anti-HIV responses. We aimed to also evaluate potential systemic humoral responses against HIV in a group of HIV-exposed seronegative individuals (HESN) in stable relationship with HIV-infected partners. Methods: We recruited 27 serodiscordant couples. HESN were classified according to HIV exposure into very low/low and moderate/high risk. Plasma from HESN and HIV+ partners were tested for neutralizing capacity and for the recognition of cell-surface expressed and recombinant forms of HIV envelope glycoproteins (Env). Healthy individuals (healthy control, n = 11) were used as controls. Results: Recognition of cell-surface expressed Env by both immunoglobulin (Ig) G and IgA was higher in plasma samples from HESN than in healthy controls (P = 0.0062 and P = 0.0144, respectively). IgG binding to Env was significantly increased in HESN after unmasking CD4-induced epitopes (P = 0.001), suggesting a wide range of targeted epitopes. Remarkably, ELISA assays using trimeric gp140 or monomeric gp120 failed to detect significant differences in reactivity between groups. Neutralization analysis showed residual activity in only three HESN samples (11%), whereas 70% of HIV-infected partners showed neutralizing activity. Although anti-Env humoral responses were found in 85% of HESN, their magnitude was not associated with the estimated level of exposure or the detection of HIV-specific cellular immune responses. Conclusion: A high proportion of HESN show detectable plasma IgG or IgA recognizing different exposed and cryptic Env native epitopes unrelated to neutralizing capacity. Therefore, low but persistent HIV exposure induces new virus-specific systemic humoral responses or boosts preexisting natural antibodies. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins

Filiaciones:
:
 Inst Invest Ciencies Salut Germans Trias & Pujol, Inst Recerca SIDA IrsiCaixa HIVACAT, Badalona, Spain

Restrepo, C:
 Hosp Carlos III, Dept Infect Dis, Madrid, Spain

Rallon, NI:
 Hosp Carlos III, Dept Infect Dis, Madrid, Spain

:
 Inst Invest Ciencies Salut Germans Trias & Pujol, Inst Recerca SIDA IrsiCaixa HIVACAT, Badalona, Spain

del Romero, J:
 Inst Invest Sanitaria San Carlos IdISSC, Ctr Sanitario Sandoval, Madrid, Spain

Rodriguez, C:
 Inst Invest Sanitaria San Carlos IdISSC, Ctr Sanitario Sandoval, Madrid, Spain

Soriano, V:
 Hosp Carlos III, Dept Infect Dis, Madrid, Spain

:
 Inst Invest Ciencies Salut Germans Trias & Pujol, Inst Recerca SIDA IrsiCaixa HIVACAT, Badalona, Spain

 Inst Invest Ciencies Salut Germans Trias & Pujol, Fundacio Lluita SIDA, Badalona, Spain

Benito, JM:
 Hosp Carlos III, Dept Infect Dis, Madrid, Spain

:
 Inst Invest Ciencies Salut Germans Trias & Pujol, Inst Recerca SIDA IrsiCaixa HIVACAT, Badalona, Spain
ISSN: 02699370





AIDS
Editorial
Lippincott Williams & Wilkins Ltd., TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 27 Número: 9
Páginas: 1375-1385
WOS Id: 000330519100003
ID de PubMed: 23945502

MÉTRICAS